electroCore, Inc. (NASDAQ:ECOR – Get Free Report) Director Thomas Errico purchased 5,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were bought at an average price of $9.85 per share, for a total transaction of $49,250.00. Following the completion of the purchase, the director directly owned 343,332 shares in the company, valued at $3,381,820.20. This represents a 1.48% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
electroCore Price Performance
NASDAQ ECOR opened at $9.97 on Monday. The company has a fifty day moving average of $7.68 and a two-hundred day moving average of $7.06. The company has a market capitalization of $89.93 million, a PE ratio of -6.01 and a beta of 0.93. electroCore, Inc. has a 1 year low of $4.41 and a 1 year high of $10.49.
electroCore (NASDAQ:ECOR – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. electroCore had a negative return on equity of 1,956.38% and a negative net margin of 39.96%.The business had revenue of $9.45 million for the quarter, compared to analysts’ expectations of $9.49 million. On average, research analysts expect that electroCore, Inc. will post -1.4 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.00.
Get Our Latest Research Report on electroCore
electroCore Company Profile
electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.
The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.
Featured Articles
- Five stocks we like better than electroCore
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
